Pfizer/Merck KGaA scrap a pivotal trial, partly because it tested Bavencio against what is no longer the relevant standard of care.
Probiodrug grabs $15m, but it will need more to fund phase IIb development of its Alzheimer’s candidate, PQ912.
The battle for dominance of the transcatheter aortic valve market has shifted to new territory. And once again, Edwards Lifesciences is winning.
For Urovant, beating placebo in a pivotal trial of vibegron was the easy part.
Another vast trial is on the cards for Apple’s ECG, and ought to yield more meaningful data.
The long overdue readout of a pivotal birch pollen allergy vaccine trial draws a blank for the beleaguered UK company.
An Icer white paper provides ammunition for both PBMs and pharma before the next Capitol Hill hearing.
Scholar Rock selects a lead molecule inhibiting TGF-β, an increasingly important oncology mechanism that Glaxosmithkline recently paid €300m to enter.
The UK ortho and woundcare group might yet pounce on Nuvasive.